反应详情

Using the procedure outlined in Example 1(g) the title compound was prepared from 4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenylamine (from Example 70(B)), 73 mg, 0.28 mmol) and 8-cyclohexyl-2-methanesulfonyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester (from Example 17(e), 100 mg, 0.26 mmol). The title compound was obtained as a white solid (40 mg, 25%). 1H NMR (400 MHz, CDCl3) δ (ppm): 9.21 (s, 1H), 8.99 (s, 1H), 8.41 (s, 1H), 7.47 (d, J=8.5 Hz, 2H), 7.13 (d, J=8.5 Hz, 2H), 4.96 (m, 3H), 4.31 (q, J=7.1 Hz, 2H), 3.00 (m, 4H), 2.77 (m, 1H), 2.30 (s, 6H), 1.93 (m, 6H), 1.64 (m, 5H), 1.42 (m, 2H), 1.34 (t, J=7.1 Hz, 3H), 1.18(m, 1H).